27 completed, 13 unknown, 4 terminated, 3 withdrawn. 49 Phase 1, 27 Phase 2.
Follow Chronic Limb-Threatening Ischemia: new trials by email Literature Review of Chronic Limb-Threatening Ischemia trials Research Report on Chronic Limb-Threatening Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma/Stem Cells (AdMSC) Transplantation in Patients With Critical Limb Ischemia. Adipose tissue derived mesenchymal Stroma/stem Cells transplantation - Critical Limb Ischemia | Phase 1 | Not yet recruiting | University Hospital, Toulouse | 10 | 2025-01-01 | 2025-01-28 |
| Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia EPCs, Clinical standard treatment (CST) - Critical Limb Ischemia | Phase 1 | Unknown | Allife Medical Science and Technology Co., Ltd. | 27 | 2024-04-01 | 2024-04-11 |
| YQ23 Study in Patients With Critical Limb Ischaemia YQ23, Matching placebo - Critical Limb Ischemia | Phase 1 / Phase 2 | Terminated | New Beta Innovation Limited | 5 | 2021-03-10 | 2023-12-08 |
| Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial), Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial) - Critical Limb Ischemia | Phase 1 / Phase 2 | Completed | S.Biomedics Co., Ltd. | 20 | 2020-11-04 | 2024-08-30 |
| Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction Rejuveinix Low Dose, Rejuveinix High Dose - Critical Limb Ischemia, Peripheral Arterial Disease | Phase 1 / Phase 2 | Unknown | Reven Pharmaceuticals, Inc. | 320 | 2020-01-01 | 2018-08-09 |
| A Safety and Efficacy Study of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia Cellgram-CLI - Critical Limb Ischemia | Phase 1 | Withdrawn | Pharmicell Co., Ltd. | 2019-12-01 | 2019-03-22 | |
| Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT AAV-hTERT - Critical Limb Ischemia | Phase 1 | Unknown | Libella Gene Therapeutics | 5 | 2019-09-26 | 2019-10-28 |
| Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia Cell-based therapy - Chronic Limb-threatening Ischemia, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | 24 | 2019-01-01 | 2022-11-30 |
| Recombinant SeV-hFGF2/dF Injection for PAOD Recombinant SeV-hFGF2/dF Injection - PAOD - Peripheral Arterial Occlusive Disease, PAD | Phase 1 | Unknown | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 12 | 2018-09-05 | 2018-10-25 |
| A Safety and Tolerability Study of RJX Drug Product in Healthy Participants RJX, Placebo - Critical Limb Ischemia | Phase 1 | Completed | Reven Pharmaceuticals, Inc. | 76 | 2018-08-24 | 2020-04-27 |
| Autologous BMMNC Combined With HA Therapy for PAOD RV-P1501 - Peripheral Arterial Occlusive Disease, Critical Limb Ischemia | Phase 1 / Phase 2 | Withdrawn | Academia Sinica, Taiwan | 2017-01-17 | 2022-03-15 | |
| Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA) Injection of cBMA aspirate into the index leg - Peripheral Artery Disease, Vascular Disease | Phase 1 | Completed | Michael Murphy | 6 | 2017-01-06 | 2024-12-12 |
| Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK) vonapanitase, Placebo - Peripheral Artery Disease | Phase 1 | Completed | Proteon Therapeutics | 29 | 2016-11-01 | 2019-05-02 |
| Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia ADRC injection, ADRC isolation, Liposuction - Critical Limb Ischemia, Arteriosclerosis Obliterans | Phase 1 / Phase 2 | Unknown | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 9 | 2016-07-01 | 2016-08-12 |
| BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) BGC101 (autologous EnEPC preparation), Control medium - Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | Phase 1 / Phase 2 | Active not recruiting | BioGenCell Ltd. | 40 | 2016-06-01 | 2025-06-06 |
| Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease Allogenic MSC, Normal saline - Critical Limb Ischemia | Phase 1 | Completed | Taiwan Bio Therapeutics Inc. | 18 | 2015-05-01 | 2021-08-25 |
| Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia 20 million hMSCs, 40 million hMSCs, 80 million hMSCs - Critical Limb Ischemia | Phase 1 | Completed | National University of Ireland, Galway, Ireland | 12 | 2015-03-23 | 2021-03-04 |
| To Evaluate the Safety and Efficacy of IM and IV Administration of Autologous ADMSCs for Treatment of CLI Autologous Stromal Vascular Fraction (SVF), Autologous Adipose Derieved MSCs, Control - Critical Limb Ischemia | Phase 1 / Phase 2 | Unknown | Kasiak Research Pvt. Ltd. | 60 | 2014-08-01 | 2014-05-23 |
| Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia Liposuction, Stem Cell Injection - Critical Limb Ischemia | Phase 1 | Withdrawn | Ageless Regenerative Institute | 2014-03-01 | 2017-07-21 | |
| Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study Ticagrelor - Critical Limb Ischemia | Phase 1 / Phase 2 | Completed | University of Southern California | 53 | 2014-02-16 | 2019-06-19 |
Showing 20 of 49. Sign in to see all of them.
Peripheral Arterial Disease (16) · Peripheral Vascular Diseases (14) · Diabetic Foot (4) · Leg Ulcer (4) · Arterial Occlusive Diseases (3) · Ischemia (3) · Peripheral Arterial Occlusive Disease 1 (3) · Thromboangiitis Obliterans (3) · Diabetes Mellitus (2) · Gangrene (2) · Vascular Diseases (2) · Arteriosclerosis Obliterans (1) · Constriction, Pathologic (1) · Diabetes Complications (1)
Arteriosclerosis (49) · Atherosclerosis (49) · Cardiovascular Diseases (49) · Chronic Disease (49) · Disease Attributes (49) · Pathologic Processes (49) · Pathological Conditions, Signs and Symptoms (49) · Vascular Diseases (47) · Arterial Occlusive Diseases (46) · Ischemia (46) · Peripheral Vascular Diseases (35) · Peripheral Arterial Disease (33) · Endocrine System Diseases (7) · Skin Diseases (7) · Skin Ulcer (7)
Cell- and Tissue-Based Therapy (2) · Lipectomy (2) · Saline Solution (2) · Standard of Care (2) · Drug Therapy (1) · Granulocyte Colony-Stimulating Factor (1) · Plasmalyte A (1) · Sodium Chloride (1) · Ticagrelor (1) · ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine hydrochloride, riboflavin 5' phosphate, niacinamide, pyridoxine hydrochloride, and calcium D-pantothenate drug combination (1) · cholesterol-binding protein (1) · holo-(acyl-carrier-protein) synthase (1)
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (3) · Losordo, Douglas, M.D. (2) · Pluristem Ltd. (2) · Reven Pharmaceuticals, Inc. (2) · Academia Sinica, Taiwan (1) · Ageless Regenerative Institute (1) · Aldagen (1) · Allife Medical Science and Technology Co., Ltd. (1) · Apceth GmbH & Co. KG (1) · Arteriocyte, Inc. (1) · Beike Biotech India Pvt.ltd (1) · BioGenCell Ltd. (1) · Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation (1) · Federal Research Clinical Center of Federal Medical & Biological Agency, Russia (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1)
United States (17) · India (5) · China (4) · Israel (3) · Spain (3) · Colombia (2) · Germany (2) · Russia (2) · Taiwan (2) · Brazil (1) · France (1) · Hong Kong (1) · Ireland (1) · Italy (1) · Netherlands (1)
Michael P Murphy, MD (2) · Alexander Reyzelman, MD (1) · Alisha Oropallo, MD (1) · Amish N Raval, MD (1) · Andrey A Kalinin, MD, PhD (1) · Andrey A Pulin, MD, PhD (1) · Antonio Chacon, MD, PhD (1) · Antonio De la Cuesta, MD (1) · Attilio Odero, Professor (1) · Bernat Soria (1) · Billy Lau (1) · Caitlin Hicks, MD (1) · Chun Che Shih (1) · Dennis A Ruff, MD (1) · Diego Martinez, MD, PhD (1)
PMID 35802393, PMID 19301723, PMID 21594960, PMID 23192920, PMID 23758736, PMID 24218170, PMID 25239491, PMID 25567765, PMID 26148006, PMID 26428987, PMID 26526721, PMID 33144352, PMID 33244300, PMID 35721744, PMID 36052743, PMID 37626416, PMID 37740111
2008 (1), 2023 (1)